Trial Profile
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 31 May 2022 Planned End Date changed from 30 Nov 2022 to 30 Nov 2024.
- 31 May 2022 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2024.
- 26 May 2022 Planned primary completion date changed from 30 Nov 2021 to 30 Nov 2022.